SCHEMBL8937405

SCHEMBL8937405

CCOc1ccc(/C(=C\C(=O)O)c2cccc(F)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TP53 P04637 3/20 0.47
NR4A2 P43354 1/20 0.47
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
MAOB P27338 3/20 0.46
CHRNA7 P36544 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
HPGD P15428 1/20 0.45
MAPT P10636 3/20 0.45
PPARG P37231 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937407 1.00 LMNA (0.57) LMNAALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL8937402 1.00 LMNA (0.57) LMNAALDH1A1SMN1; SMN2KDM4EMAPK1
SCHEMBL8937488 0.85 ALDH1A1 (0.60) LMNAALDH1A1SMN1; SMN2KDM4ETP53
SCHEMBL8937491 0.85 ALDH1A1 (0.60) LMNAALDH1A1SMN1; SMN2KDM4ETP53
SCHEMBL8937486 0.85 ALDH1A1 (0.60) LMNAALDH1A1SMN1; SMN2KDM4ETP53
SCHEMBL11296725 0.78 ALDH1A1 (0.54) LMNAALDH1A1SMN1; SMN2KDM4ERELA
SCHEMBL11891940 0.78 ALDH1A1 (0.54) LMNAALDH1A1SMN1; SMN2KDM4ERELA
SCHEMBL11296722 0.78 ALDH1A1 (0.54) LMNAALDH1A1SMN1; SMN2KDM4ERELA
SCHEMBL8937333 0.77 MAOB (0.48) LMNAALDH1A1MAPK1L3MBTL1MAOB
SCHEMBL8937340 0.77 MAOB (0.48) LMNAALDH1A1MAPK1L3MBTL1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed